JP6310470B2 - 前立腺がんを処置するための方法 - Google Patents
前立腺がんを処置するための方法 Download PDFInfo
- Publication number
- JP6310470B2 JP6310470B2 JP2015540806A JP2015540806A JP6310470B2 JP 6310470 B2 JP6310470 B2 JP 6310470B2 JP 2015540806 A JP2015540806 A JP 2015540806A JP 2015540806 A JP2015540806 A JP 2015540806A JP 6310470 B2 JP6310470 B2 JP 6310470B2
- Authority
- JP
- Japan
- Prior art keywords
- androgen
- cells
- prostate cancer
- cdk8
- cdk19
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 206010060862 Prostate cancer Diseases 0.000 title claims description 57
- 208000000236 Prostatic Neoplasms Diseases 0.000 title claims description 57
- 238000000034 method Methods 0.000 title description 7
- 239000003098 androgen Substances 0.000 claims description 121
- 108010080146 androgen receptors Proteins 0.000 claims description 66
- 102100032187 Androgen receptor Human genes 0.000 claims description 62
- 102100024456 Cyclin-dependent kinase 8 Human genes 0.000 claims description 58
- 101000980937 Homo sapiens Cyclin-dependent kinase 8 Proteins 0.000 claims description 58
- 102100033145 Cyclin-dependent kinase 19 Human genes 0.000 claims description 38
- 101000944345 Homo sapiens Cyclin-dependent kinase 19 Proteins 0.000 claims description 38
- 230000000694 effects Effects 0.000 claims description 26
- 239000003112 inhibitor Substances 0.000 claims description 20
- 230000004913 activation Effects 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 10
- 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 claims description 9
- 239000003446 ligand Substances 0.000 claims description 8
- 230000015572 biosynthetic process Effects 0.000 claims description 7
- 238000003786 synthesis reaction Methods 0.000 claims description 7
- 108010057466 NF-kappa B Proteins 0.000 claims description 5
- 230000003834 intracellular effect Effects 0.000 claims description 4
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 claims description 4
- 229940124639 Selective inhibitor Drugs 0.000 claims description 3
- 230000004544 DNA amplification Effects 0.000 claims description 2
- 206010064571 Gene mutation Diseases 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 97
- 230000014509 gene expression Effects 0.000 description 39
- VNADJTWHOAMTLY-UHFFFAOYSA-N 4-[2-[6-(4-methylpiperazine-1-carbonyl)naphthalen-2-yl]ethylamino]quinazoline-6-carbonitrile Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(C=C(CCNC=2C3=CC(=CC=C3N=CN=2)C#N)C=C2)C2=C1 VNADJTWHOAMTLY-UHFFFAOYSA-N 0.000 description 27
- 239000002609 medium Substances 0.000 description 24
- 102100038358 Prostate-specific antigen Human genes 0.000 description 23
- 230000012010 growth Effects 0.000 description 22
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 21
- 101000605528 Homo sapiens Kallikrein-2 Proteins 0.000 description 18
- 102100038356 Kallikrein-2 Human genes 0.000 description 18
- 206010028980 Neoplasm Diseases 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 230000001419 dependent effect Effects 0.000 description 15
- 230000005764 inhibitory process Effects 0.000 description 13
- CCCIJQPRIXGQOE-XWSJACJDSA-N 17beta-hydroxy-17-methylestra-4,9,11-trien-3-one Chemical compound C1CC2=CC(=O)CCC2=C2[C@@H]1[C@@H]1CC[C@](C)(O)[C@@]1(C)C=C2 CCCIJQPRIXGQOE-XWSJACJDSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- 230000035897 transcription Effects 0.000 description 11
- 238000013518 transcription Methods 0.000 description 11
- 230000011664 signaling Effects 0.000 description 10
- 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 9
- WXCXUHSOUPDCQV-UHFFFAOYSA-N enzalutamide Chemical compound C1=C(F)C(C(=O)NC)=CC=C1N1C(C)(C)C(=O)N(C=2C=C(C(C#N)=CC=2)C(F)(F)F)C1=S WXCXUHSOUPDCQV-UHFFFAOYSA-N 0.000 description 9
- 230000002103 transcriptional effect Effects 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 101001091365 Homo sapiens Plasma kallikrein Proteins 0.000 description 7
- 101000605534 Homo sapiens Prostate-specific antigen Proteins 0.000 description 7
- 201000011510 cancer Diseases 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- 230000004044 response Effects 0.000 description 7
- XBJCNHGQFJFCOY-UHFFFAOYSA-N 4-(2-phenylethylamino)quinazoline-6-carbonitrile Chemical compound C12=CC(C#N)=CC=C2N=CN=C1NCCC1=CC=CC=C1 XBJCNHGQFJFCOY-UHFFFAOYSA-N 0.000 description 6
- 206010009944 Colon cancer Diseases 0.000 description 6
- 201000008808 Fibrosarcoma Diseases 0.000 description 6
- 102100030875 Gastricsin Human genes 0.000 description 6
- 241000699670 Mus sp. Species 0.000 description 6
- 101710191567 Probable endopolygalacturonase C Proteins 0.000 description 6
- 208000029742 colonic neoplasm Diseases 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 230000010261 cell growth Effects 0.000 description 5
- 230000002950 deficient Effects 0.000 description 5
- 229960004671 enzalutamide Drugs 0.000 description 5
- 230000001605 fetal effect Effects 0.000 description 5
- 238000003119 immunoblot Methods 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 210000003734 kidney Anatomy 0.000 description 5
- 230000001105 regulatory effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108090000331 Firefly luciferases Proteins 0.000 description 4
- 102100033299 Glia-derived nexin Human genes 0.000 description 4
- 101000997803 Homo sapiens Glia-derived nexin Proteins 0.000 description 4
- 101000638154 Homo sapiens Transmembrane protease serine 2 Proteins 0.000 description 4
- 241000699660 Mus musculus Species 0.000 description 4
- 102000003945 NF-kappa B Human genes 0.000 description 4
- 238000011529 RT qPCR Methods 0.000 description 4
- 102100031989 Transmembrane protease serine 2 Human genes 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 238000011580 nude mouse model Methods 0.000 description 4
- 238000002560 therapeutic procedure Methods 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- 206010002261 Androgen deficiency Diseases 0.000 description 3
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 3
- 108091000080 Phosphotransferase Proteins 0.000 description 3
- 239000000051 antiandrogen Substances 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000012091 fetal bovine serum Substances 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 230000003211 malignant effect Effects 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 102000020233 phosphotransferase Human genes 0.000 description 3
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 3
- 210000000064 prostate epithelial cell Anatomy 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- 108091007914 CDKs Proteins 0.000 description 2
- 102100024457 Cyclin-dependent kinase 9 Human genes 0.000 description 2
- 102100031181 Glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 101000980930 Homo sapiens Cyclin-dependent kinase 9 Proteins 0.000 description 2
- 101000992298 Homo sapiens Kappa-type opioid receptor Proteins 0.000 description 2
- 101001139130 Homo sapiens Krueppel-like factor 5 Proteins 0.000 description 2
- 101000864800 Homo sapiens Serine/threonine-protein kinase Sgk1 Proteins 0.000 description 2
- 101000820490 Homo sapiens Syntaxin-binding protein 6 Proteins 0.000 description 2
- 102100031819 Kappa-type opioid receptor Human genes 0.000 description 2
- 102100020680 Krueppel-like factor 5 Human genes 0.000 description 2
- -1 PSA (KLK3) Chemical compound 0.000 description 2
- 102100030070 Serine/threonine-protein kinase Sgk1 Human genes 0.000 description 2
- 102100021681 Syntaxin-binding protein 6 Human genes 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000001548 androgenic effect Effects 0.000 description 2
- 229940030486 androgens Drugs 0.000 description 2
- 230000002280 anti-androgenic effect Effects 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 238000001794 hormone therapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 108020001756 ligand binding domains Proteins 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 108020004999 messenger RNA Proteins 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 230000009456 molecular mechanism Effects 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 210000002307 prostate Anatomy 0.000 description 2
- 230000007420 reactivation Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000004614 tumor growth Effects 0.000 description 2
- 102100022289 60S ribosomal protein L13a Human genes 0.000 description 1
- 101150029129 AR gene Proteins 0.000 description 1
- 229940123407 Androgen receptor antagonist Drugs 0.000 description 1
- 108060000903 Beta-catenin Proteins 0.000 description 1
- 102000015735 Beta-catenin Human genes 0.000 description 1
- 108010077544 Chromatin Proteins 0.000 description 1
- 102000008169 Co-Repressor Proteins Human genes 0.000 description 1
- 108010060434 Co-Repressor Proteins Proteins 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 108700039887 Essential Genes Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000681240 Homo sapiens 60S ribosomal protein L13a Proteins 0.000 description 1
- 108010080991 Mediator Complex Proteins 0.000 description 1
- 102000000490 Mediator Complex Human genes 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102100021010 Nucleolin Human genes 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 101150010842 PGC gene Proteins 0.000 description 1
- 108010044843 Peptide Initiation Factors Proteins 0.000 description 1
- 102000005877 Peptide Initiation Factors Human genes 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 102000009822 Sterol Regulatory Element Binding Proteins Human genes 0.000 description 1
- 108010020396 Sterol Regulatory Element Binding Proteins Proteins 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 1
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 1
- 102000004243 Tubulin Human genes 0.000 description 1
- 108090000704 Tubulin Proteins 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- GZOSMCIZMLWJML-VJLLXTKPSA-N abiraterone Chemical compound C([C@H]1[C@H]2[C@@H]([C@]3(CC[C@H](O)CC3=CC2)C)CC[C@@]11C)C=C1C1=CC=CN=C1 GZOSMCIZMLWJML-VJLLXTKPSA-N 0.000 description 1
- 229960000853 abiraterone Drugs 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 239000000556 agonist Substances 0.000 description 1
- 230000003042 antagnostic effect Effects 0.000 description 1
- 229940030495 antiandrogen sex hormone and modulator of the genital system Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 230000009400 cancer invasion Effects 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 210000003855 cell nucleus Anatomy 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 210000003483 chromatin Anatomy 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000003889 eye drop Substances 0.000 description 1
- 229940012356 eye drops Drugs 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002601 intratumoral effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 230000005937 nuclear translocation Effects 0.000 description 1
- 108010044762 nucleolin Proteins 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003076 paracrine Effects 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 208000023958 prostate neoplasm Diseases 0.000 description 1
- 230000017854 proteolysis Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- 108090000721 thyroid hormone receptors Proteins 0.000 description 1
- 102000004217 thyroid hormone receptors Human genes 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000005026 transcription initiation Effects 0.000 description 1
- 108091006106 transcriptional activators Proteins 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261721134P | 2012-11-01 | 2012-11-01 | |
| US61/721,134 | 2012-11-01 | ||
| PCT/US2013/067990 WO2014071143A1 (en) | 2012-11-01 | 2013-11-01 | Method for treating prostate cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016501845A JP2016501845A (ja) | 2016-01-21 |
| JP2016501845A5 JP2016501845A5 (enExample) | 2016-12-22 |
| JP6310470B2 true JP6310470B2 (ja) | 2018-04-11 |
Family
ID=49641849
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015540806A Expired - Fee Related JP6310470B2 (ja) | 2012-11-01 | 2013-11-01 | 前立腺がんを処置するための方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9636342B2 (enExample) |
| EP (1) | EP2914266B1 (enExample) |
| JP (1) | JP6310470B2 (enExample) |
| KR (1) | KR20160014568A (enExample) |
| CA (1) | CA2890108C (enExample) |
| WO (1) | WO2014071143A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106282378A (zh) * | 2016-09-28 | 2017-01-04 | 湖北工业大学 | 一种用于细胞周期依赖性蛋白激酶8基因突变检测的试剂及应用 |
| WO2019055977A1 (en) | 2017-09-18 | 2019-03-21 | Chan Zuckerberg Biohub, Inc. | METHODS OF TREATING NEGATIVE TRIPLE BREAST CANCER |
| US11014906B2 (en) | 2018-08-21 | 2021-05-25 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| US12281080B2 (en) | 2018-08-21 | 2025-04-22 | University Of South Carolina | Quinoline-based compounds and methods of inhibiting CDK8/19 |
| CA3128377A1 (en) * | 2019-02-01 | 2020-08-06 | University Of South Carolina | Bicyclic pyridine compositions and methods of using the same for cancer therapy |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2005327921A1 (en) * | 2004-11-01 | 2006-08-31 | University Of Southern California | Novel compounds for treatment of cancer and disorders associated with angiogenesis function |
| US8598344B2 (en) | 2009-11-30 | 2013-12-03 | Senex Biotechnology | CDKI pathway inhibitors and uses thereof |
| EP2547661A2 (en) * | 2010-03-16 | 2013-01-23 | Dana-Farber Cancer Institute, Inc. | Indazole compounds and their uses |
| EA027531B1 (ru) | 2011-09-13 | 2017-08-31 | Игорь Ронинсон | ЛЕЧЕНИЕ ЗАБОЛЕВАНИЙ И НАРУШЕНИЙ, ВЫЗВАННЫХ АКТИВНОСТЬЮ ТРАНСКРИПЦИОННОГО ФАКТОРА NF-κB |
| KR20150023223A (ko) | 2012-02-02 | 2015-03-05 | 세넥스 바이오테크놀러지 인코포레이티드 | Ｃｄｋ8/ｃｄｋ19 선택성 억제제 및 암에 대한 항-전이 및 화학예방 방법에서 이들의 용도 |
-
2013
- 2013-11-01 JP JP2015540806A patent/JP6310470B2/ja not_active Expired - Fee Related
- 2013-11-01 WO PCT/US2013/067990 patent/WO2014071143A1/en not_active Ceased
- 2013-11-01 KR KR1020157014380A patent/KR20160014568A/ko not_active Ceased
- 2013-11-01 US US14/439,127 patent/US9636342B2/en active Active
- 2013-11-01 CA CA2890108A patent/CA2890108C/en active Active
- 2013-11-01 EP EP13795625.6A patent/EP2914266B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2890108C (en) | 2021-03-02 |
| EP2914266A1 (en) | 2015-09-09 |
| JP2016501845A (ja) | 2016-01-21 |
| EP2914266B1 (en) | 2019-06-19 |
| US20150272953A1 (en) | 2015-10-01 |
| WO2014071143A1 (en) | 2014-05-08 |
| KR20160014568A (ko) | 2016-02-11 |
| US9636342B2 (en) | 2017-05-02 |
| CA2890108A1 (en) | 2014-05-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102871388B1 (ko) | 암을 치료하는 방법 | |
| Li et al. | Berberine suppresses androgen receptor signaling in prostate cancer | |
| JP2022084888A (ja) | 子宮頸がんを処置するためのグルココルチコイドレセプターモジュレーター | |
| He et al. | Potent activity of the Hsp90 inhibitor ganetespib in prostate cancer cells irrespective of androgen receptor status or variant receptor expression | |
| Galimberti et al. | Targeting the cyclin E-Cdk-2 complex represses lung cancer growth by triggering anaphase catastrophe | |
| JP6310470B2 (ja) | 前立腺がんを処置するための方法 | |
| JP2018513123A (ja) | Ｒｏｒガンマ阻害剤を用いてがんを治療するための方法 | |
| KR20130118870A (ko) | 유방암 치료제 | |
| EP4585273A2 (en) | Mechanism of resistance to bet bromodomain inhibitors | |
| EP3213752B1 (en) | Composition for treating cancer stem cells | |
| Ouanouki et al. | Periostin, a signal transduction intermediate in TGF-β-induced EMT in U-87MG human glioblastoma cells, and its inhibition by anthocyanidins | |
| Hsieh et al. | Cell suspension culture extract of Eriobotrya japonica attenuates growth and induces apoptosis in prostate cancer cells via targeting SREBP-1/FASN-driven metabolism and AR | |
| KR20190018486A (ko) | 암의 예방 및/또는 치료를 위한 화합물, 조성물 및 방법 | |
| CA2993118A1 (en) | Combination comprising pterostilbene for the treatment of cancer | |
| Caruana et al. | Site-1 protease, a novel metabolic target for glioblastoma | |
| JP2014509608A (ja) | 前立腺癌を治療するための、抗クラステリンオリゴヌクレオチドとｈｓｐ９０阻害剤との併用 | |
| Xu et al. | Combination of an anti-EGFRvIII antibody CH12 with Rapamycin synergistically inhibits the growth of EGFRvIII+ PTEN− glioblastoma in vivo | |
| Tovar et al. | MDM2 antagonists boost antitumor effect of androgen withdrawal: implications for therapy of prostate cancer | |
| Deng et al. | DC120, a novel and potent inhibitor of AKT kinase, induces tumor cell apoptosis and suppresses tumor growth | |
| Ye et al. | Loss of PI (4, 5) P2 5-phosphatase A contributes to resistance of human melanoma cells to RAF/MEK inhibitors | |
| CN108434137B (zh) | 一种治疗前列腺癌的组合物 | |
| US20170258793A1 (en) | Method for treating prostate cancer | |
| KR101207981B1 (ko) | 호르몬 불응성 전립선암의 예방 또는 치료용 약제학적 조성물 및 그의 스크리닝 방법 | |
| Yang et al. | Antimetastatic activity of MONCPT in preclinical melanoma mice model | |
| JP6969778B2 (ja) | 誤りがちｄｎａ修復経路の抑制によるがんの治療 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20161101 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20161101 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20170803 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20171106 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20180104 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20180202 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20180214 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20180316 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6310470 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| LAPS | Cancellation because of no payment of annual fees |